MX2020008663A - Anticuerpos anti-angiopoyetina-2 y usos de los mismos. - Google Patents
Anticuerpos anti-angiopoyetina-2 y usos de los mismos.Info
- Publication number
- MX2020008663A MX2020008663A MX2020008663A MX2020008663A MX2020008663A MX 2020008663 A MX2020008663 A MX 2020008663A MX 2020008663 A MX2020008663 A MX 2020008663A MX 2020008663 A MX2020008663 A MX 2020008663A MX 2020008663 A MX2020008663 A MX 2020008663A
- Authority
- MX
- Mexico
- Prior art keywords
- ang2
- antibodies
- abnormal
- tie2
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862633038P | 2018-02-20 | 2018-02-20 | |
| KR1020190018769A KR102497171B1 (ko) | 2018-02-20 | 2019-02-18 | 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도 |
| PCT/KR2019/001983 WO2019164219A1 (en) | 2018-02-20 | 2019-02-19 | Anti-angiopoietin-2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008663A true MX2020008663A (es) | 2021-02-09 |
Family
ID=67775161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008663A MX2020008663A (es) | 2018-02-20 | 2019-02-19 | Anticuerpos anti-angiopoyetina-2 y usos de los mismos. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11498962B2 (https=) |
| EP (1) | EP3755714A4 (https=) |
| JP (2) | JP7366068B2 (https=) |
| KR (1) | KR102497171B1 (https=) |
| CN (1) | CN111741975B (https=) |
| AU (1) | AU2019224694B2 (https=) |
| CA (1) | CA3091613A1 (https=) |
| MX (1) | MX2020008663A (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102497171B1 (ko) | 2018-02-20 | 2023-02-08 | 기초과학연구원 | 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도 |
| KR20220002143A (ko) * | 2020-06-30 | 2022-01-06 | 삼성전자주식회사 | 항-Ang2 항체를 포함하는 코로나바이러스 감염증을 치료하기 위한 조성물 및 그의 용도 |
| US20230312698A1 (en) * | 2020-08-07 | 2023-10-05 | Nanjing GenScript Biotech Co., Ltd. | Antibodies against human angiopoietin-2 and uses thereof |
| CN116209765B (zh) * | 2020-08-19 | 2025-11-07 | 药物抗体公司 | 经修饰抗体及其制备方法 |
| JP7749696B2 (ja) * | 2021-04-23 | 2025-10-06 | ニオテスバイオ インコーポレイテッド | アンジオポエチン－２に特異的に結合する抗体、またはその断片 |
| KR102459211B1 (ko) * | 2021-04-23 | 2022-10-26 | (주)니오테스바이오 | 안지오포이에틴-2에 특이적으로 결합하는 항체, 또는 이의 단편 |
| KR20250128899A (ko) * | 2024-02-20 | 2025-08-28 | 주식회사 맵틱스 | Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도 |
| WO2025186364A1 (en) | 2024-03-06 | 2025-09-12 | Jeansson Marie | Angpt2-targeting antibodies for use in the treatment of fibrotic diseases, particularly kidney disease(s), disorder(s) or injury associated with kidney fibrosis |
| CN121231772B (zh) * | 2025-12-02 | 2026-03-17 | 武汉市金银潭医院(武汉市传染病医院) | 抗体夹心法检测猴痘病毒a29l蛋白的试剂或试剂盒及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| BRPI0519596B1 (pt) | 2004-12-21 | 2022-01-18 | Astrazeneca Ab | Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado |
| US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US8980268B2 (en) * | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
| CA2844306C (en) | 2011-08-19 | 2022-08-16 | Regeneron Pharmaceuticals, Inc. | Anti-tie2 antibodies and uses thereof |
| EP2835380B2 (en) * | 2013-07-29 | 2021-04-07 | Samsung Electronics Co., Ltd | Method of blocking vascular leakage using an anti-Ang2 antibody |
| KR102146845B1 (ko) | 2013-07-30 | 2020-08-21 | 삼성전자주식회사 | 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
| KR102196450B1 (ko) | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
| US9994632B2 (en) | 2014-05-26 | 2018-06-12 | Samsung Electronics Co., Ltd. | Humanized or affinity-matured anti Ang-2 antibody and uses thereof |
| CA2963606A1 (en) | 2014-11-10 | 2016-05-19 | F.Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| KR102497171B1 (ko) | 2018-02-20 | 2023-02-08 | 기초과학연구원 | 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도 |
-
2019
- 2019-02-18 KR KR1020190018769A patent/KR102497171B1/ko active Active
- 2019-02-19 AU AU2019224694A patent/AU2019224694B2/en active Active
- 2019-02-19 MX MX2020008663A patent/MX2020008663A/es unknown
- 2019-02-19 EP EP19757411.4A patent/EP3755714A4/en active Pending
- 2019-02-19 CA CA3091613A patent/CA3091613A1/en active Pending
- 2019-02-19 CN CN201980014282.1A patent/CN111741975B/zh active Active
- 2019-02-19 JP JP2020566520A patent/JP7366068B2/ja active Active
-
2020
- 2020-08-17 US US16/995,707 patent/US11498962B2/en active Active
-
2022
- 2022-10-12 US US18/045,964 patent/US12331106B2/en active Active
-
2023
- 2023-10-10 JP JP2023175308A patent/JP2024009914A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20230272057A1 (en) | 2023-08-31 |
| CN111741975B (zh) | 2025-02-18 |
| CN111741975A (zh) | 2020-10-02 |
| JP2024009914A (ja) | 2024-01-23 |
| EP3755714A4 (en) | 2022-02-16 |
| KR102497171B1 (ko) | 2023-02-08 |
| CA3091613A1 (en) | 2019-08-29 |
| US12331106B2 (en) | 2025-06-17 |
| US11498962B2 (en) | 2022-11-15 |
| JP7366068B2 (ja) | 2023-10-20 |
| KR20190100060A (ko) | 2019-08-28 |
| EP3755714A1 (en) | 2020-12-30 |
| US20210079083A1 (en) | 2021-03-18 |
| AU2019224694A1 (en) | 2020-08-06 |
| AU2019224694B2 (en) | 2025-09-04 |
| JP2021514670A (ja) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008663A (es) | Anticuerpos anti-angiopoyetina-2 y usos de los mismos. | |
| MX2018010374A (es) | Inhibidores del enlace proteína-proteína de wdr5. | |
| EA202190377A1 (ru) | Композиции ингибиторов cxcr4 и способы получения и применения | |
| HK1250513A1 (zh) | 抗ox40抗体及其使用方法 | |
| MX2019012818A (es) | Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos. | |
| WO2019098763A3 (ko) | 알파-시누클레인에 대한 항체 및 그 용도 | |
| MX2019004779A (es) | Composicion farmaceutica para tratamiento y/o prevencion de cancer. | |
| CO2017001875A2 (es) | Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| GT201200258A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
| RU2010127291A (ru) | Терапевтическое средство от зуда | |
| ZA202304227B (en) | Antibodies that bind to il1rap and uses thereof | |
| EA201791710A1 (ru) | Антитела к транстиретину | |
| WO2020198055A9 (en) | Allosteric bcr-abl proteolysis targeting chimeric compounds | |
| MX2018004043A (es) | Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados. | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| MX2019015741A (es) | Tratamiento con plasminogeno de afecciones asociadas a la sobreexpresion de pai-1. | |
| WO2014205072A3 (en) | FC RECEPTOR (FcRn) BINDING PEPTIDES AND USES THEREOF | |
| EA201990988A1 (ru) | Антитела против chikv и пути их применения | |
| WO2019165158A8 (en) | Il-6 inhibitors and methods of treatment | |
| WO2019089753A3 (en) | Cd137 antibodies and pd-1 antagonists and uses thereof | |
| WO2019028182A3 (en) | TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40) | |
| WO2012174488A3 (en) | Agents and methods for treating ischemic and other diseases | |
| BR112022010424A2 (pt) | Tratamento para sobrecarga de ferro fisiológica |